Eton Pharmaceuticals Inc. (NASDAQ: ETON) reported Q4 EPS of $0.19, $0.01 better than the analyst estimate of $0.18. Revenue for the quarter came in at $21.3 million versus the consensus estimate of $21.96 million.

For earnings history and earnings-related data on Eton Pharmaceuticals Inc. (ETON) click here.